Phthalic Acid

Phthalic Acid

SCHEMBL322997

O=C(O)c1ccccc1.O=C(O)c1ccccc1C(=O)O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D

The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.78
ALDH1A1 P00352 3/20 0.78
NAPRT Q6XQN6 2/20 0.78
DAO P14920 1/20 0.78
ALOX15 P16050 1/20 0.78
AKR1C3 P42330 3/20 0.73
CES2 O00748 1/20 0.64
CES1 P23141 1/20 0.64
SRD5A2 P31213 1/20 0.64
KDM4E B2RXH2 2/20 0.59
TP53 P04637 1/20 0.58
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
HMGB1 P09429 1/20 0.56
HPGD P15428 1/20 0.56
CA4 P22748 1/20 0.56
CA6 P23280 1/20 0.56
CA7 P43166 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phthalic Acid SCHEMBL4578569 1.00 TSHR (0.78) TSHRALDH1A1NAPRTDAOALOX15
Phthalic Acid SCHEMBL30665138 1.00 TSHR (0.78) TSHRALDH1A1NAPRTDAOALOX15
Phthalic Acid SCHEMBL5078834 0.97 TSHR (0.74) TSHRALDH1A1NAPRTDAOALOX15
Phthalic Acid SCHEMBL28331573 0.97 TSHR (0.74) TSHRALDH1A1NAPRTDAOALOX15
Phthalic Acid SCHEMBL29055925 0.97 TSHR (0.74) TSHRALDH1A1NAPRTDAOALOX15
Terephthalic Acid SCHEMBL108623 0.94 ALDH1A1 (0.78) TSHRALDH1A1NAPRTDAOALOX15
Terephthalic Acid SCHEMBL7796434 0.92 ALDH1A1 (0.74) TSHRALDH1A1NAPRTDAOALOX15
Phthalic Acid SCHEMBL7750890 0.91 ALDH1A1 (0.64) TSHRALDH1A1NAPRTDAOALOX15
Benzoic Acid SCHEMBL7719037 0.88 TSHR (1.00) TSHRALDH1A1NAPRTDAOALOX15
Phthalic Acid SCHEMBL1808 0.88 ALDH1A1 (1.00) TSHRALDH1A1NAPRTDAOALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240203666-A1 Advanced Polymer Dispersion and a Capacitor on its Base KEMET ELECTRONICS CORPORATION 2024-06-20 US claimed
WO-2023095183-A1 A PHARMACEUTICAL COMPOSITION AND A SOLID DOSAGE FORM THEREOF JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (JO) 2023-06-01 WO claimed
US-20230135608-A1 PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE AS AN ACTIVE INGREDIENT PROVIDES A SPECIFIC PHARMACOKINETIC PARAMETER CURACLE CO., LTD. (KR) 2023-05-04 US claimed
US-20230058942-A1 EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE SUN PHARMACEUTICAL IND LTD (IN) 2023-02-23 US claimed
CN-113645962-A Enteric coated tablet containing dimethyl fumarate 库拉科有限公司 2021-11-12 CN claimed
US-20210228488-A1 EXTENDED RELEASE COMPOSITIONS AND PROCESS FOR PREPARATION RUBICON RES PRIVATE LIMITED (IN) 2021-07-29 US claimed
US-20210106537-A1 EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE SUN PHARMACEUTICAL IND LTD (IN) 2021-04-15 US claimed
US-10898444-B2 Extended release multiparticulates of ranolazine SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2021-01-26 US claimed
WO-2020242132-A1 ENTERIC TABLET CONTAINING DIMETHYL FUMARATE 주식회사 큐라클 2020-12-03 WO claimed
EP-1898886-B1 NOVEL SUSTAINED RELEASE DOSAGE FORM RUBICON RES PVT LTD (IN) 2019-09-04 EP claimed
EP-0515626-B1 STERILISING COMPOSITION CITROSIL SANITAS SPA (IT) 1995-12-27 EP claimed
WO-1995016739-A1 STABILISED VINYL CHLORIDE COMPOSITION AKCROS CHEMICALS (GB) 1995-06-22 WO claimed
EP-0515626-A1 STERILISING COMPOSITION. GLAXO SPA (IT) 1992-12-02 EP claimed
WO-1992010935-A1 STERILISING COMPOSITION GLAXO S.P.A. (IT) 1992-07-09 WO claimed
EP-0122815-B1 ENTERIC-SOLUBLE PREPARATIONS AND A PROCESS FOR THEIR PRODUCTION SANKYO COMPANY LIMITED (JP) 1989-10-25 EP claimed
EP-0108504-B1 A PROCESS FOR COATING SOLID PHARMACEUTICAL PREPARATIONS AND COATED PREPARATIONS THUS OBTAINED SANKYO COMPANY LIMITED (JP) 1987-05-13 EP claimed
US-4661162-A MIXTURE OF POLYMER WITH POLYANIONIC POLYMER WHICH IS SOLUBLE AT LOW PH SANKYO COMPANY, LIMITED (JP) 1987-04-28 US claimed
US-4497847-A MONO AND DIESTERS OF GLYCEROL AND SATURATED CARBOXYLIC ACIDS AS PLASTICIZERS SANKYO COMPANY, LIMITED (JP) 1985-02-05 US claimed
EP-0122815-A1 Enteric-soluble preparations and a process for their production SANKYO COMPANY LIMITED (JP) 1984-10-24 EP claimed
EP-0108504-A1 A process for coating solid pharmaceutical preparations and coated preparations thus obtained SANKYO COMPANY LIMITED (JP) 1984-05-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135608-A1 PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE AS AN ACTIVE INGREDIENT PROVIDES A SPECIFIC PHARMACOKINETIC PARAMETER SLC5A2, FH, SLC5A1 TSHR 4784/4885ALDH1A1 1455/4885NAPRT 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.